TITLE

Research Capsules

PUB. DATE
April 2007
SOURCE
Pharmaceutical Representative;Apr2007, Vol. 37 Issue 4, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article provides updates of drug clinical trials in the U.S. According to a French study, transdermal forms of hormone therapy may carry a lower risk of blood clots than oral hormone therapy. Meanwhile, adding investigational drug Genasense injection to chemotherapy may increase response rates in patients with relapsed or refractory chronic lymphocytic leukemia. Moreover, Noxafil by Schering-Plough Corp. is said to prevent invasive fungal infections in immunocompromized patients effectively. INSET: Oracea.
ACCESSION #
24619970

 

Related Articles

  • 2012 American Society of Clinical Oncology Annual Meeting: Experimental agent may help older people with chronic leukemia.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article offers information on a clinical trial study which reveals that the drug ibrutinib has the potential to treat elderly patients with chronic lymphocytic leukemia.

  • United Kingdom : GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL.  // TendersInfo News;8/1/2014, p1 

    The article reports on the announcement by pharmaceutical company GSK and biotechnology company Genmab on August 1, 2014 of positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed chronic lymphocytic leukaemia (CLL).

  • Clinic Roundup.  // BioWorld Today;2/16/2011, Vol. 22 Issue 32, p7 

    This section offers news briefs on clinical trials including the positive results obtained by Advancell SL from a Phase I/IIa trial of its chronic lymphocytic leukemia candidate, the effectiveness of Alkermes Incorporated's candidate for opioid induced bowel dysfunction, and the recommendation...

  • Antidote. Siegel, Marc // Medical Marketing & Media;Sep2011, Vol. 46 Issue 9, p12 

    The article discusses how the new treatment for chronic lymphocytic leukemia (CLL) works as a clinical trial at the University of Pennsylvania succeeded.

  • Obinutuzumab plus chlorambucil improved outcomes in untreated CLL. Altersitz, Katrina; Todak, Alexandra // Hem/Onc Today;2/10/2014, Vol. 15 Issue 3, p32 

    The article reports the results of a clinical trial which revealed that patients with previously untreated chronic lymphocytic leukemia (CLL) showed improved progression-free survival rates after being treated with obinutuzumab plus chlorambucil, instead of rituxumab plus chlorambucil.

  • Lenalidomide associated with durable remissions in elderly patients with symptomatic CLL.  // Hem/Onc Today;8/10/2011, Vol. 12 Issue 15, p22 

    The article reports on the results from a phase 2 study conducted at the University of Texas MD Anderson Cancer Center which showed that lenalidomide is associated with durable remissions in elderly patients with chronic lymphocytic leukemia (CLL).

  • Phase III leukaemia drug trial halted due to high death rate.  // Reactions Weekly;7/20/2013, Issue 1462, p2 

    The article reports on the Celgene Corp.'s announcement that it will discontinue its Phase III ORIGIN clinical trial, which evaluates the efficacy and safety of lenalidomide versus chlorambucil in chronic lymphocytic leukemia patients, due to high death rate among patients in the lenalidomide arm.

  • Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Tse, Eric; Leung, Rock; Kwong, Yok-Lam // Annals of Hematology;Jan2015, Vol. 94 Issue 1, p165 

    A letter to the editor is presented which discusses cases of development of invasive fungal infections following obinutuzumab monotherapy for refractory chronic lymphocytic leukemia.

  • Cephalon Files Second Treanda NDA, Seeks Approval In NHL.  // BioWorld Today;1/2/2008, Vol. 19 Issue 1, p2 

    The article reports on the application of Cephalon Inc. for Treanda as first-line treatment of chronic lymphocytic leukemia (CLL) patients. Cephalon of Frazer, Pennsylvania is basing the submission on data from a pivotal, 100-patient study of Treanda in non-Hodgkin's lymphoma (NHL). The National...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics